Gap, Ulta Beauty and America Eagle fall premarket; Zscaler gains

Investing.com -- U.S. stock futures slipped slightly lower Friday ahead of the release of key inflation data, amid increased uncertainty over President Donald Trump’s tariffs regime.

Here are some of the biggest premarket U.S. stock movers today:

• Gap (NYSE:GAP) (NYSE:GAP) stock dropped 14% after the clothes retailer delivered another strong quarterly earnings beat, but said tariffs could cost the company between $100 million and $150 million, with mitigation efforts.

• Ulta Beauty (NASDAQ:ULTA) stock rose 9.3% after the cosmetics company boosted its full-year outlook after beating first-quarter expectations, signalling that shoppers are keeping up with non-essential beauty purchases.

• Dell Technologies (NYSE:DELL) stock rose 0.8% after the tech giant lifted full-year earnings guidance despite reporting mixed Q1 results as earnings missed estimates on a tariffs-related hit to demand.

• Marvell (NASDAQ:MRVL) stock fell 3.4% despite forecasting second-quarter revenue above expectations, betting on strong demand for its custom chips powering artificial intelligence workloads in data centers.

• Costco (NASDAQ:COST) stock slipped 0.1% despite the warehouse retailer posted better-than-anticipated fiscal third-quarter earnings as inflation-wary consumers continue to bulk-buy goods amid worries about tariff-related price hikes ahead.

• American Eagle Outfitters (NYSE:AEO) stock slumped 7% after the retailer forecast second-quarter revenue below estimates after reporting a wider-than-expected quarterly loss, due to rising input costs and sluggish demand.

• Zscaler (NASDAQ:ZS) stock rose 3.9% after the cloud security company reported better-than-expected earnings for its fiscal third quarter and raised its outlook, while also naming Kevin Rubin as its chief financial officer.

• Sanofi (NASDAQ:SNY) ADRs fell 4.9% and Regeneron (NASDAQ:REGN) stock dropped 8.8% after the pharmaceutical companies reported disappointing results from two phase 3 trials of their investigational chronic obstructive pulmonary disease treatment, Itepekimab.

• Palantir (NASDAQ:PLTR) stock rose 0.4% after a New York Times (NYSE:NYT) report detailing the company’s increasing involvement with the Trump administration’s data-sharing initiatives.